Hodgkin Lymphoma Survivors Face Quality of Life Deficits Decades After Diagnosis

The Long Shadow of Survivorship in Hodgkin Lymphoma

Significant progress in therapeutic protocols and early detection has led to a continuous decline in cancer mortality, with over 4 million deaths averted in the United States since 1991 [1, 2, 3]. This success has created a rapidly expanding population of survivors, which is projected to reach 22.1 million by 2030 [4]. While acute treatment toxicities are well-documented, the medical community is increasingly focused on the long-term psychosocial and physical needs of patients who live decades past their diagnosis [5]. In Hodgkin lymphoma specifically, high clinical cure rates necessitate a deeper understanding of whether survivors regain a quality of life comparable to their healthy peers, particularly as research indicates progressive declines in cardiorespiratory fitness (the capacity of the cardiovascular and respiratory systems to supply oxygen during sustained physical activity) and increased fatigue in this population [6]. A new nationwide analysis provides critical data on the persistence of symptomatic burdens among these long-term survivors.

Nationwide Cohort and Multidimensional Assessment

The researchers conducted a Danish, nationwide, cross-sectional analysis (an observational study that captures data at a single point in time across a population) to evaluate the long-term quality of life among individuals previously diagnosed with Hodgkin lymphoma. To provide a robust baseline for comparison, each patient with Hodgkin lymphoma was matched in a 1:10 ratio to comparators from the general population. The study cohort included 1777 patients with Hodgkin lymphoma, representing a 42% response rate from the 4156 individuals invited to participate. This clinical group was compared against 6166 matched individuals from the general population, who had a 14% response rate out of 41,558 invitees. The demographic profile of the participants was closely aligned, with a median age of 59 years in the Hodgkin lymphoma group and 61 years among the comparators. Within the patient cohort, the vast majority of cases were characterized as classical Hodgkin lymphoma, accounting for 92% of the participants.

To capture a comprehensive picture of survivorship, the study utilized four validated multidimensional assessment tools. These included the HeartQoL (a questionnaire specifically designed to measure health-related quality of life in patients with heart disease), the European Organization for Research and Treatment of Cancer Quality of Life Core-30 (QLQ-C30, a tool assessing the physical, psychological, and social functions of cancer patients), the Short Form-36 (SF-36, a generic survey of health status), and the EuroQoL Health Questionnaire (EQ-5D, a standardized instrument for measuring generic health outcomes). By employing these diverse instruments, the researchers were able to evaluate specific domains ranging from cardiac-related symptoms to general physical and emotional well-being. This rigorous methodology allowed for a detailed comparison of how the long-term health status of Hodgkin lymphoma survivors deviates from that of the general population across multiple facets of daily life, providing clinicians with a clearer understanding of the functional deficits that persist after successful oncological treatment.

Persistent Deficits Across Multiple Health Domains

To quantify the impact of the disease on long-term survivorship, the researchers utilized linear regression to estimate mean differences (MD) in quality of life scores, adjusting for the confounding variables of sex and age. The data were stratified by time since diagnosis into three distinct cohorts: 0 to 5 years, more than 5 to 10 years, and more than 10 years. Across every measured time interval, the Hodgkin lymphoma groups exhibited consistently and significantly lower quality of life scores compared to their respective matched comparators from the general population. Although the relative difference between the survivors and the control group decreased from the initial baseline to the period exceeding 10 years post-diagnosis, the deficits remained clinically relevant throughout the study period.

The impact on cardiac-related quality of life was evident in the HeartQoL scores, where the mean differences were -0.27 for the 0 to 5 year group, -0.28 for the 5 to 10 year group, and -0.24 for those more than 10 years post-diagnosis. Similar persistent deficits were observed in the European Organization for Research and Treatment of Cancer Quality of Life Core-30 (QLQ-C30) summary scores. In this domain, survivors showed mean differences of -7.4 points at 0 to 5 years, -7.6 points at 5 to 10 years, and -5.6 points after more than a decade, indicating that the burden of disease and treatment side effects does not fully resolve even with long-term survival. These point differences are significant because they exceed the thresholds typically considered to represent a noticeable change in patient-reported well-being.

Physical health status, as measured by the Short Form-36 (SF-36) physical component summary, also demonstrated significant lags compared to the general population. The mean differences were recorded at -4.5 points for the 0 to 5 year interval, -4.9 points for the 5 to 10 year interval, and -4.2 points for survivors beyond 10 years. General health utility, captured by the EQ-5D index (a standardized instrument for measuring generic health outcomes), mirrored these trends with mean differences of -0.05 in both the 0 to 5 year and 5 to 10 year cohorts, and -0.04 in the group more than 10 years post-diagnosis. These data points underscore that while the gap between survivors and the general population narrows slightly over time, the physical and functional impairments associated with Hodgkin lymphoma persist for decades, suggesting that the biological or psychological impact of the malignancy and its treatment leaves a permanent mark on the patient's health trajectory.

Clinical Implications for Long-Term Survivorship Care

The persistence of health deficits in Hodgkin lymphoma survivors suggests that clinical recovery does not necessarily equate to a return to baseline health status. While the relative difference between survivors and the general population decreased slightly over time, the quality of life deficits remained clinically important at more than 10 years post-diagnosis. For the practicing clinician, these findings indicate that the late effects of the disease or its treatment, such as chemotherapy and radiation, continue to manifest as measurable functional impairments long after the completion of active therapy. The data show that reductions in quality of life compared with the general population persist even beyond the 10-year mark, necessitating a shift in how long-term survivorship is managed in the primary care and oncology settings.

Among the various health domains assessed, the researchers identified specific symptomatic drivers that contribute most significantly to the ongoing burden of disease. The most pronounced symptoms reported by survivors were fatigue and dyspnea (shortness of breath). These symptoms are particularly relevant as they directly impact physical functioning and the ability to maintain daily activities. The presence of chronic dyspnea and fatigue more than a decade after diagnosis suggests that survivors may be living with subclinical or overt pulmonary or cardiac late effects that require ongoing monitoring. Because these symptoms are often multifactorial, the authors emphasize the need for a multidisciplinary approach to survivorship care that addresses the complex interplay of physical and psychological health in this population. For the physician, this means that a patient in remission for 10 years may still require targeted screening for cardiopulmonary dysfunction and structured interventions to manage chronic fatigue.

References

1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer Journal for Clinicians. 2024. doi:10.3322/caac.21820

2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA A Cancer Journal for Clinicians. 2023. doi:10.3322/caac.21763

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer Journal for Clinicians. 2019. doi:10.3322/caac.21551

4. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA A Cancer Journal for Clinicians. 2019. doi:10.3322/caac.21565

5. Siegel RL, DeSantis C, Virgo KS, et al. Cancer treatment and survivorship statistics, 2012. CA A Cancer Journal for Clinicians. 2012. doi:10.3322/caac.21149

6. Colella D, Monacis D. ASSESSING THE EFFECTS OF PHYSICAL ACTIVITY ON CHILDREN AND ADOLESCENTS HODGKIN’S LYMPHOMA SURVIVORS: A SYSTEMATIC REVIEW. 2021. doi:10.46827/EJPE.V6I12.3691